Opioids Market Size, Share, Growth, and Industry Analysis, By Type (Oxycodone, Hydromorphone, Codeine, Fentanyl, Other), By Application (Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression, Deaddiction, Others), Regional Insights and Forecast to 2034

Opioids Market Overview

The Opioids - Market size was valued at USD 11185.91 million in 2025 and is expected to reach USD 18247.89 million by 2034, growing at a CAGR of 5.5% from 2025 to 2034.

The Opioids Market represents a tightly regulated global pharmaceutical segment supplying more than 300 million patients annually for acute and chronic pain management. Globally, over 100 million surgical procedures require opioid-based analgesia each year, while cancer-related pain affects nearly 55% of 19 million new cancer cases diagnosed annually. Morphine-equivalent opioid consumption exceeds 40,000 defined daily doses per million inhabitants in high-income regions. More than 20 active opioid molecules are commercially manufactured, and over 60% of global opioid prescriptions are concentrated in 5 countries. Controlled substance scheduling frameworks cover 100% of marketed opioid formulations.

In the United States, the Opioids Market accounts for nearly 45% of global prescription opioid consumption volume. Over 80 million opioid prescriptions were dispensed in 2023, compared to 255 million in 2012, reflecting a 68% reduction over 11 years. Approximately 8.9 million individuals reported past-year prescription opioid misuse, while 2.5 million people were diagnosed with opioid use disorder. More than 6 million surgical procedures annually involve opioid administration. Federal and state regulations monitor 100% of Schedule II opioid prescriptions through prescription drug monitoring programs implemented across all 50 states.

• 

  Download Free sample to learn more about this report.

Key Findings

• Key Market Driver:Over 60% of postoperative patients require opioid analgesics; 55% of cancer patients experience moderate-to-severe pain; 70% of trauma cases involve opioid administration; 40% of palliative care regimens include strong opioids.
• Major Market Restraint:More than 30% prescription decline since 2016; 100% states enforce monitoring programs; 25% reduction in high-dose prescriptions; 50% decrease in extended-release opioid initiation.
• Emerging Trends:Abuse-deterrent formulations represent 35% of branded opioids; 20% increase in buprenorphine utilization; 45% growth in non-oral delivery systems; 30% adoption of digital prescribing tools.
• Regional Leadership:North America holds 45% consumption share; Europe accounts for 25%; Asia-Pacific contributes 20%; Middle East & Africa represent 5%; Latin America comprises 5%.
• Competitive Landscape:Top 5 manufacturers control 60% supply volume; 2 companies account for over 35% branded extended-release share; generic products represent 70% prescription volume; 15% share held by specialty pharma.
• Market Segmentation:Pain relief accounts for 65% application share; anesthesia 15%; cough suppression 8%; diarrhea suppression 5%; deaddiction 5%; others 2%.
• Recent Development:40% increase in naloxone distribution; 25% rise in medication-assisted treatment adoption; 30% expansion in abuse-deterrent patents; 15% increase in transdermal approvals.

Opioids Market Latest Trends

The Opioids Market Trends indicate a structural shift toward regulated prescribing and safer formulations, with more than 70% of new branded launches incorporating abuse-deterrent technologies. Extended-release opioids represent nearly 30% of long-acting prescriptions, while immediate-release formulations account for 60% of total dispensed units. Medication-assisted treatment drugs such as buprenorphine have seen over 20% prescription growth year-over-year in multiple developed regions. Transdermal opioid systems account for 12% of chronic pain opioid delivery, compared to 8% 5 years ago.

Globally, more than 110 countries classify opioids under international narcotics control treaties, covering 100% of export and manufacturing quotas. In hospital settings, 90% of major surgeries rely on opioid-based anesthesia protocols. Overdose reversal agent distribution increased by 40% between 2022 and 2024, reflecting expanded public health measures. Digital prescription monitoring now covers 95% of retail pharmacy transactions in developed economies, reducing high-dose dispensing by 25%. The Opioids Market Analysis highlights that 50% of oncology pain regimens still depend on morphine-equivalent therapy despite diversification efforts.

Opioids Market Dynamics

DRIVER

Rising demand for surgical and chronic pain management.

More than 310 million major surgical procedures are performed globally each year, with approximately 60% requiring opioid analgesia during perioperative care. Chronic pain affects over 1.5 billion individuals worldwide, representing nearly 20% of the adult population. Cancer incidence reached 19 million new cases annually, with 55% reporting moderate-to-severe pain requiring opioid therapy. In palliative care, nearly 80% of end-stage patients receive strong opioids such as morphine or fentanyl. Orthopedic surgeries, totaling over 25 million annually, rely on opioids in 70% of recovery protocols. The Opioids Market Growth is therefore closely linked to demographic aging, as individuals aged over 65 represent 10% of the global population but account for nearly 35% of opioid prescriptions.

RESTRAINT

Stringent regulations and prescription monitoring programs.

Over 100 countries enforce national narcotics control laws, and 100% of U.S. states operate prescription drug monitoring systems. Since 2016, high-dose opioid prescriptions declined by 25%, and total prescription volume fell by nearly 40% in certain regions. More than 50% of physicians report stricter prescribing thresholds compared to 5 years ago. Regulatory agencies reduced manufacturing quotas by approximately 20% between 2018 and 2023. Insurance prior authorization requirements increased by 30%, limiting patient access. The Opioids Industry Analysis reflects compliance costs rising by 15% due to serialization, electronic tracking, and reporting mandates covering 100% of controlled shipments.

OPPORTUNITY

Expansion of abuse-deterrent and deaddiction therapies.

Abuse-deterrent formulations now represent 35% of branded opioid prescriptions, compared to less than 10% a decade ago. Medication-assisted treatment programs expanded coverage to over 2 million patients globally. Buprenorphine prescriptions increased by 20% year-over-year in 2023, and naloxone distribution rose by 40%. Governments allocated 25% more funding to addiction treatment initiatives over 3 years. Telehealth-enabled opioid use disorder management accounts for 30% of treatment initiations in developed markets. The Opioids Market Opportunities are strengthened by regulatory incentives granting 5-year exclusivity extensions for abuse-deterrent innovation in certain jurisdictions.

CHALLENGE

Public health concerns and overdose mortality.

Globally, opioid-related overdose deaths exceed 100,000 annually, with synthetic opioids contributing to over 70% of fatalities in certain countries. Emergency department visits related to opioid misuse account for 5% of total drug-related admissions. Nearly 10% of prescribed patients report some level of misuse behavior. Litigation exposure increased by 50% over 5 years, affecting 15 major manufacturers. Public awareness campaigns reduced new opioid initiation rates by 30%, impacting demand patterns. The Opioids Market Forecast must account for these mortality statistics and policy responses affecting 100% of supply chain participants.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The Opioids Market Segmentation is structured by type and application, with pain relief accounting for 65% of total demand. Immediate-release opioids represent 60% of prescriptions, while extended-release account for 30%. Hospital utilization comprises 40% of distribution volume, and retail pharmacies account for 55%. Deaddiction therapies contribute 5% of overall opioid-related pharmaceutical consumption.

By Type

Oxycodone:Oxycodone accounts for nearly 30% of prescription opioid volume in developed markets. More than 20 million prescriptions annually include oxycodone-based formulations. Extended-release oxycodone represents 15% of chronic pain regimens. Abuse-deterrent oxycodone products comprise 40% of branded oxycodone sales volume. Hospital procurement includes oxycodone in 50% of orthopedic postoperative protocols. Prescription decline exceeded 35% over 7 years due to regulatory tightening.

Hydromorphone:Hydromorphone represents approximately 10% of hospital opioid utilization. It is 5 times more potent than morphine on a milligram basis. Injectable hydromorphone is used in 60% of intensive care opioid administrations. Over 5 million prescriptions annually include hydromorphone in North America. Extended-release hydromorphone contributes 20% of its total prescription share. Oncology-related pain accounts for nearly 40% of hydromorphone demand.

Codeine:Codeine accounts for 15% of mild-to-moderate pain prescriptions globally. It is included in 25% of opioid-containing cough syrups. Pediatric restrictions reduced codeine pediatric prescriptions by 50% over 5 years. Combination analgesics containing codeine represent 30% of low-dose opioid tablets. Approximately 10 million codeine prescriptions are issued annually in Europe.

Fentanyl:Fentanyl is 50 to 100 times more potent than morphine and accounts for 20% of hospital opioid potency-adjusted consumption. Transdermal fentanyl patches represent 12% of chronic cancer pain therapy. Injectable fentanyl is used in 80% of general anesthesia protocols. Over 5 million surgical cases annually utilize fentanyl-based anesthesia in the U.S. Synthetic fentanyl analogs contribute to over 70% of illicit opioid fatalities.

Other:Other opioids including morphine, methadone, tramadol, and buprenorphine account for 25% combined market volume. Morphine remains on the essential medicines list in over 100 countries. Methadone supports more than 1 million deaddiction patients globally. Tramadol accounts for 20% of prescriptions in certain emerging markets. Buprenorphine represents 5% of total opioid prescriptions but 40% of medication-assisted treatment regimens.

By Application

Pain Relief:Pain relief dominates with 65% share, serving over 1.5 billion chronic pain sufferers. Postoperative pain accounts for 40% of opioid pain use. Cancer pain contributes 20%. Musculoskeletal disorders represent 25% of opioid-treated conditions. Over 300 million surgeries annually require opioid analgesia.

Anesthesia:Anesthesia represents 15% application share. Opioids are used in 90% of general anesthesia procedures. Fentanyl and remifentanil are included in 80% of surgical sedation protocols. Over 100 million inpatient surgeries annually utilize opioid-based anesthesia.

Cough Suppression:Cough suppression accounts for 8% share. Codeine-containing syrups represent 25% of prescription antitussives. Adult prescriptions account for 70% of codeine cough usage. Pediatric use declined by 50% due to safety restrictions.

Diarrhea Suppression:Diarrhea suppression holds 5% share, primarily through loperamide and diphenoxylate. Over 10 million prescriptions annually include opioid-based antidiarrheals. Hospital use accounts for 40% of severe diarrhea cases requiring pharmacologic control.

Deaddiction:Deaddiction represents 5% share. Medication-assisted treatment serves over 2 million individuals. Buprenorphine accounts for 60% of outpatient opioid use disorder therapy. Methadone clinics support nearly 1 million patients worldwide.

Others:Other applications account for 2%, including dyspnea management and procedural sedation. Nearly 15% of palliative dyspnea cases involve low-dose morphine.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

• Global opioid consumption exceeds 40,000 defined daily doses per million inhabitants in high-income regions.
• 45% consumption concentrated in North America.
• 25% in Europe.
• 20% in Asia-Pacific.
• 5% in Middle East & Africa.

North America

North America accounts for 45% of global opioid consumption volume. The U.S. dispenses over 80 million prescriptions annually, compared to 255 million in 2012. Canada reports nearly 15,000 defined daily doses per million inhabitants annually. Medication-assisted treatment coverage exceeds 1.5 million patients. Over 70% of overdose fatalities involve synthetic opioids. Hospital utilization accounts for 40% of medical opioid distribution. Abuse-deterrent formulations represent 50% of branded extended-release opioids.

Europe

Europe holds 25% of global share. Approximately 10 million codeine prescriptions are issued annually. Morphine consumption exceeds 12,000 defined daily doses per million inhabitants in Western Europe. Over 30 countries enforce centralized opioid monitoring. Cancer incidence of 4 million annually supports 50% opioid use in oncology pain. Hospital procurement accounts for 45% of regional volume.

Asia-Pacific

Asia-Pacific contributes 20% share. Japan and Australia account for 60% of regional medical opioid consumption. Cancer incidence exceeds 9 million cases annually. Opioid consumption per capita remains below 5,000 defined daily doses per million inhabitants in several emerging economies. Regulatory reforms increased monitored prescriptions by 25% over 3 years. Surgical volumes exceed 100 million annually across the region.

Middle East & Africa

Middle East & Africa account for 5% of global share. Morphine availability improved by 20% in 10 years. Cancer incidence exceeds 1 million annually. Less than 30% of severe pain patients receive adequate opioid therapy. Hospital-based distribution represents 70% of regional supply. Regulatory frameworks expanded coverage to 80% of tertiary hospitals.

List of Top Opioids Companies

• Teva
• Purdue Pharma
• Mallinckrodt
• Amneal Pharma
• Collegium
• J&J
• Endo
• Pfizer
• INSYS
• Mylan
• Hikma
• Egalet

Top 2 companies by market share

• Teva: Holds approximately 18% global generic opioid volume share, supplying over 30 opioid formulations across 60 countries.
• Mallinckrodt: Accounts for nearly 15% hospital injectable opioid supply volume in North America, with over 20 controlled substance SKUs.

Investment Analysis and Opportunities

The Opioids Market Research Report indicates over 25% increase in investment toward abuse-deterrent technologies over 5 years. More than 30 pipeline candidates target extended-release or tamper-resistant formulations. Public funding for opioid use disorder programs increased by 25% between 2021 and 2024. Over 50 clinical trials are evaluating next-generation opioid-sparing analgesics. Manufacturing modernization projects improved serialization compliance to 100% digital traceability in developed markets. More than 15% of R&D budgets among leading manufacturers are allocated to addiction mitigation and safer opioid design initiatives.

New Product Development

New product development focuses on 3 primary areas: abuse-deterrent tablets, long-acting injectables, and digital adherence monitoring. Over 35% of newly approved opioids since 2020 include tamper-resistant features. Transdermal systems increased by 15% in approvals over 5 years. Subcutaneous depot buprenorphine injections provide 30-day therapeutic coverage with 95% adherence rates. Extended-release morphine microspheres demonstrate 24-hour analgesic duration in 80% of treated patients. More than 20 patents filed annually relate to opioid formulation improvements. Digital pill tracking systems show 25% reduction in misuse rates during pilot programs.

Five Recent Developments (2023–2025)

1. 2023: A leading manufacturer expanded abuse-deterrent oxycodone production by 20% to meet 15% increased hospital demand.
2. 2023: Naloxone over-the-counter availability expanded nationwide, increasing distribution volume by 40%.
3. 2024: A 30-day injectable buprenorphine received expanded indication covering 80% of outpatient addiction clinics.
4. 2024: Manufacturing quotas adjusted downward by 10% to align with 25% prescription decline trends.
5. 2025: Digital prescription integration achieved 95% pharmacy network coverage, reducing high-dose dispensing by 20%.

Report Coverage of Opioids Market

The Opioids Market Report covers analysis of over 20 opioid molecules across 4 regions and 12 key countries. The Opioids Industry Report evaluates 300+ data points including prescription volume, defined daily doses per million inhabitants, regulatory frameworks in 100+ countries, and 50+ pipeline products. The Opioids Market Outlook includes segmentation by 5 types and 6 applications, supported by 10-year historical prescription data trends. Over 70% of branded products and 100% of generic high-volume formulations are assessed. The Opioids Market Insights incorporate hospital utilization rates of 40%, retail distribution share of 55%, and deaddiction therapy penetration of 5%, delivering comprehensive Opioids Market Analysis for B2B stakeholders.